HRTX Heron Therapeuti

USD 2.74 0.00 0
Icon

Heron Therapeuti (HRTX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 2.74

0.00 (0.00)%

USD 0.46B

1.23M

USD 9.00(+228.47%)

USD 4.00 (+45.99%)

Icon

HRTX

Heron Therapeuti (USD)
COMMON STOCK | NSD
USD 2.74
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 0.46B

USD 4.00 (+45.99%)

USD 2.74

Heron Therapeuti (HRTX) Stock Forecast

USD 9.00
(+228.47%)

Based on the Heron Therapeuti stock forecast from 1 analysts, the average analyst target price for Heron Therapeuti is USD 9.00 over the next 12 months. Heron Therapeuti’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Heron Therapeuti is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Heron Therapeuti’s stock price was USD 2.74. Heron Therapeuti’s stock price has changed by -10.16% over the past week, +0.00% over the past month and +58.38% over the last year.

No recent analyst target price found for Heron Therapeuti
No recent average analyst rating found for Heron Therapeuti

Company Overview Heron Therapeuti

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technolo...Read More

https://www.herontx.com

4242 Campus Point Court, San Diego, CA, United States, 92121

126

December

USD

USA

Adjusted Closing Price for Heron Therapeuti (HRTX)

Loading...

Unadjusted Closing Price for Heron Therapeuti (HRTX)

Loading...

Share Trading Volume for Heron Therapeuti Shares

Loading...

Compare Performance of Heron Therapeuti Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for HRTX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Heron Therapeuti (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.14 (-0.27%) USD107.38B 29.93 21.06

ETFs Containing HRTX

Symbol Name HRTX's Weight Expense Ratio Price(Change) Market Cap
QQQS
Invesco NASDAQ Future Gen.. 0.85 % 0.20 % +0.68 (+2.59%) USD7.59M

Frequently Asked Questions About Heron Therapeuti (HRTX) Stock

Based on ratings from 1 analysts Heron Therapeuti's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.

Unfortunately we do not have enough data on HRTX's stock to indicate if its a good dividend stock.

Based on targets from 1 analysts, the average taret price for HRTX is USD 9.00 over the next 12 months. The maximum analyst target price is USD 9 while the minimum anlayst target price is USD 9.

Unfortunately we do not have enough data on HRTX's stock to indicate if its overvalued.

The last closing price of HRTX's stock was USD 2.74.

The most recent market capitalization for HRTX is USD 0.46B.

Based on targets from 1 analysts, the average taret price for HRTX is projected at USD 9.00 over the next 12 months. This means that HRTX's stock price may go up by +228.47% over the next 12 months.

Following are ETFs with the highest allocation to Heron Therapeuti's stock :

QQQS

As per our most recent records Heron Therapeuti has 126 Employees.

Heron Therapeuti's registered address is 4242 Campus Point Court, San Diego, CA, United States, 92121. You can get more information about it from Heron Therapeuti's website at https://www.herontx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...